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Leukocyte adhesion deficiency type I (LAD-I) is a primary immunodeficiency caused by mutations in the
ITGB2 gene and is characterized by recurrent and life-threatening bacterial infections. These mutations
lead to defective or absent expression of b2 integrins on the leukocyte surface, compromising adhesion and
extravasation at sites of infection. Three different lentiviral vectors (LVs) conferring ubiquitous or pref-
erential expression of CD18 in myeloid cells were constructed and tested in human and mouse LAD-I cells.
All three hCD18-LVs restored CD18 and CD11a membrane expression in LAD-I patient-derived lym-
phoblastoid cells. Corrected cells recovered the ability to aggregate and bind to sICAM-1 after stimulation.
All vectors induced stable hCD18 expression in hematopoietic cells from mice with a hypomorphic Itgb2
mutation (CD18HYP), both in vitro and in vivo after transplantation of corrected cells into primary and
secondary CD18HYP recipients. hCD18+ hematopoietic cells from transplanted CD18HYP mice also showed
restoration of mCD11a surface co-expression. The analysis of in vivo neutrophil migration in CD18HYP
mice subjected to two different inflammation models demonstrated that the LV-mediated gene therapy
completely restored neutrophil extravasation in response to inflammatory stimuli. Finally, these vectors
were able to correct the phenotype of human myeloid cells derived from CD34+ progenitors defective
in ITGB2 expression. These results support for the first time the use of hCD18-LVs for the treatment of
LAD-I patients in clinical trials.
INTRODUCTION
LEUKOCYTE ADHESION DEFICIENCY TYPE I (LAD-I) is
an autosomal recessive primary immunodeficiency
caused by deficient cell surface expression of b2
integrins. As a consequence, neutrophils fail to
firmly adhere to the inflamed endothelium and to
extravasate from blood to infection sites. The mo-
lecular basis underlying LAD-I are mutations in
the ITGB2 gene that encodes for the b2 common
integrin subunit (CD18).1–3
LAD-I patients suffer from recurrent and life-
threatening infections that appear early in child-
hood.4 Two different phenotypes of LAD-I have
been described5: a severe phenotype, when levels of
CD18 expression are lower than 2% of normal level,
and a moderate phenotype, when levels of CD18
expression are 2–30% of the normal level. Hema-
topoietic stem cell transplantation (HSCT) is cur-
rently the only curative treatment for LAD-I.6
After several in vitro studies,7–10 the first attempt
to treat LAD-I by gene therapy (GT) was carried out
in 2000when two patients were enrolled in a phase-
I GT clinical trial.11,12 Mobilized CD34+ HSCs were
collected from peripheral blood (PB), transduced
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with a GALV-pseudotyped c-RV, and infused back
into the patients without any conditioning. A small
percentage of corrected myeloid cells (up to 0.04%)
were detected in PB up to 4 weeks after trans-
plantation, but no corrected cells were detected 2
months after transplantation.
Apart from the clinical studies shown above,
additional preclinical GT studies have been car-
ried out in a canine leukocyte adhesion deficiency
(CLAD) model typical of Irish setter dogs.13,14 The
therapeutic efficacy of different vectors has been
evaluated in this model using nonmyeloablative
conditioning. Independently of the vector—c-RV,
foamy viral vector (FV), or self-inactivating lenti-
viral vector (SINLV)—several animalswere rescued
from the disease when the expression of the canine
CD18 (cCD18) cDNAwas driven by themurine stem
cell virus (MSCV) LTR promoter/enhancer.15,16 In a
new attempt to improve the safety of this GT ap-
proach, either FV or SIN LVs carrying weaker pro-
moters were designed. However, in these cases, the
outcome of treated dogswas less conclusive.16–18 The
lack of a full myeloablative conditioning and the
transduction of target cells at low multiplicity of
infection (MOI) could account for the modest ther-
apeutic effects observed in these studies.
In our studies lentiviral vectors carrying three
different promoters to drive the expression of hCD18
were constructed. The human PGK promoter has
been extensively investigated in preclinical studies
demonstrating its ubiquitous, moderate, and stable
activity in vivo.19,20 More recently, clinical GT stud-
ies have been also conducted showing the efficacy of
this promoter in metachromatic leukodystrophy
patients.21 The A2UCOE promoter, from the hu-
man HNRPA2B1-CBX3 locus, has also been shown
to provide efficient therapeutic correction in different
preclinical disease mouse models such as SCID-X122
and recombinationactivating gene2 (RAG2)-SCID,23
with no significant adverse effects, and with little or
no methylation.24–26 We have also used a chimeric
promoter that is a fusion of the minimal 5¢-flanking
regions of cFES and the CTSG genes, which encode
for proteins expressed duringneutrophilmaturation.
This promoter drives preferential expression in my-
eloid cells and has been successfully used for hema-
topoietic ex vivoGT inamousemodel ofX-CGD27 and
is currently in clinical trial.
To evaluate the therapeutic efficacy of these
vectors, a mouse model of LAD-I with a hypomor-
phic mutation in CD18 (CD18HYP)28 was used.
Homozygous mutant CD18HYP mice exhibit im-
paired inflammatory responses, mild leukocytosis,
hyperplasia in spleen and BM, and increased con-
tent of hematopoietic progenitors and HSCs in
their BM, compared with wild-type (WT) mice.29
Additionally, in vitro studies with human LAD-I
lymphoblastic cells (LCs) and with cord blood
CD34+ cells with a downregulated expression in
CD18 were performed. Our data strongly show the
therapeutic value of hCD18-LVs, suggesting that
these vectors would efficiently restore the clinical
signs of LAD-I patients.
MATERIALS AND METHODS
Ex vivo gene therapy
For ex vivoGTexperiments, overnight-transduced
lin- cells were collected and washed and 3–5·105
cells were intravenously administered into lethally
irradiated female CD18HYP mice. PB was monthly
collected and analyzed for the expression of hCD18
and the different murine CD11 subunits. Genomic
DNA (gDNA) was used for vector copy number
(VCN) determination. Three months after trans-
plantation, animals were analyzed for hCD18 ex-
pression in the different leukocyte subpopulations.
Transplanted mice were culled at 4 months post-
transplantation (mpt) and total bone marrow
cells (BMCs) were analyzed. In total, 3 ·106 BMCs
were transplanted mouse to mouse into myeloab-
lated secondary recipients that were followed up
for 9 months.
Air-pouch inflammation model
The air pouch (AP) was generated by dorsal
subcutaneous injection of air on day 0 under iso-
flurane anesthesia. On day 3 the pouches were re-
inflated and, on day 5, 40ng of mouse recombinant
TNF-a in phosphate buffered saline (PBS) with
0.5% carboxymethylcellulose (CMC) as inert car-
rier was injected into the matured pouches. Four
hours after TNF-a administration, mice were sac-
rificed by CO2 inhalation, and PB was collected by
heart puncture and the total number of neutrophils
determined. The APs were then flushed with, and
the total neutrophils number in the AP was also
determined. Emigration ratio for total neutrophils
was calculated as follows: Emigration Ratio = (AP
neutrophils/PB neutrophils) · 100. In the case of
GT-treated animals, hCD18+ or GFP+ neutrophils
were determined in PB and in the AP, and emi-
gration ratio was calculated as follows: Emigration
Ratio = (hCD18+ or GFP+ AP neutrophils/hCD18+
or GFP+ PB neutrophils) · 100
Lipopolysaccharide-induced asthma model
Mice were intranasally administered with 50ll of
0.3lg/ll lipopolysaccharide (LPS, from Escherichia
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coli 0111:B4; Sigma-Aldrich, St. Louis, MO) or PBS
under isofluraneanesthesia. Twenty-four hours after
LPS/PBS administration, bronchoalveolar lavages
(BALs) were performed. Mice were euthanized im-
mediately before lavage by lethal injection of
avertin (synthetized in the laboratory from 2,2,2-
tribromoethanol and 2-methyl-2-butanol, both
from Sigma-Aldrich) and exsanguination. Then a
18G blunt fill needle (BD, 305180) was inserted
through a small incision in the trachea and la-
vages were collected. Cell number analysis and
FACS analysis (Ly6G/CD11c) were performed in
those samples. Absolute numbers of neutrophils
were determined as follows: Total Cell Number ·
(% Ly6GHigh CD11c- cells). Absolute numbers of
migrating neutrophils were normalized to the
values obtained in the CD18HYP animals.
RESULTS
Lentiviral-mediated phenotypic correction
of LAD-I lymphoblast cell lines
We generated three different SIN-LVs in which
the expression of hCD18 was driven by two ubiq-
uitous promoters, PGK and UCOE promoters,19–22
and by the chimeric promoter, which has prefer-
ential activity in mature myeloid cells.27 As a neg-
ative control a SFFV-eGFP-LV was used in all
experiments (Fig. 1A and Supplementary Methods;
Supplementary Data are available online at www
.liebertpub.com/hum).
Figure 1. Transduction of LAD-I lymphoblastic cells and endogenous regulation of hCD18 membrane expression. (A) hCD18 and eGFP-LV constructs used
in the different experiments. (B–G) LAD-I and HD LCs were transduced with hCD18-LVs and control eGFP-LVs. (B) Percentage of hCD18+ and hCD11a+
cells 5 days after transduction at an MOI of 10 i.u./cell. (C) Relative hCD18 surface expression corrected with the VCN. (D) LAD-I LCs VCN transduced at
increasing MOIs (from 1 to 100 i.u./cell) with LV:Chim.hCD18. (E) Percentage of hCD18/hCD11a-expressing cells after transduction with increasing MOIs
with LV:Chim.hCD18. (F) hCD18 and hCD11a mRNA expression levels relative to untransduced LCs. (G) hCD18 and hCD11a surface expression levels. HD,
healthy donor; LAD-I, leukocyte adhesion deficiency type I; LC, lymphoblastic cell; LV, lentiviral vector; MOI, multiplicity of infection; VCN, vector copy
number.
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In a first set of experiments we investigated the
efficacy of the hCD18-LVs vectors to confer hCD18
expression in human LAD-I LCs, with no detect-
able expression of hCD18 (Fig. 1B). After trans-
duction of these cells with any of the hCD18-LVs,
almost 100% of the cells expressed hCD18 on the
cell membrane (Fig. 1B). Moreover, since the trans-
location of hCD11a to the cell membrane is depen-
dent onCD18 expression, the transduction of LAD-I
cells with any of the hCD18-LVs efficiently restored
the membrane expression of hCD11a (Fig. 1B).
To determine hCD18 expression levels conferred
by the different LVs in LAD-I LCs, mean fluores-
cence intensity (MFI) values as well as mean copy
numbers of each LV were determined after trans-
duction in each population, and MFI values were
normalized per copy of integrated provirus (MFI/
VCN) (Fig. 1C). Although the UCOE promoter
seemed to confer the highest membrane expression
levels of hCD18, no significant differences were
noted between LAD-I cells transduced with any of
the hCD18-LVs, either when compared among
themselves, or when compared with LCs from a
healthy donor (HD) (p>0.05). This indicates that
the three LV constructs were able to confer physi-
ological levels of hCD18 in human LAD-I LCs.
Because CD18 is expressed in the cell mem-
brane in association with CD11, we speculated that
the ectopic membrane expression of hCD18might be
regulated by endogenous physiological levels of
hCD11. To validate this hypothesis, LAD-I LCs were
transduced with the Chim.hCD18-LV at increasing
MOIs. As expected, increases in the MOI mediated a
progressive increase in the VCN/cell (Fig. 1D), with
most cells being positive for hCD18 expression at
MOIs of 10 i.u./cell or higher (Fig. 1E). Also, hCD18
mRNA levels—but not hCD11a mRNA levels—pro-
gressively increased in parallel to VCN/cell increases
(Fig. 1F). However, the ectopic expression of both
CD18 and CD11a in the membrane of LAD-I-
transduced cells reached a plateau at an MOI of 10
i.u./cell (Fig. 1G).
To investigate whether restoration of expression
of hCD18 corrected the function of LAD-I cells, we
first performed aggregation assays in LAD-I LCs.
While 4 beta-phorbol-12-myristate-13-acetate (PMA)
induced the aggregation of eGFP-transduced HD
LCs, no aggregation was induced in eGFP-transduced
LAD-I LCs (Fig. 2A and Supplementary Methods).
Significantly, LAD-I LCs that had been trans-
duced with any of the hCD18-LVs recovered the
ability to aggregate after PMA stimulus, indicat-
ing that the ectopic expression of hCD18 was
functional. The aggregation observed in HD cells
and also in corrected LAD-I cells was abrogated in
the presence of an anti-hCD18 blocking antibody,
Figure 2. Phenotypic correction of LAD-I lymphoblastoid cells. LAD-I and HD LCs were transduced with hCD18-LVs and control eGFP-LVs at anMOI of 10 i.u./cell. (A)
PMA-induced aggregation assays. Cells were incubated with either PBS or PMA and let to aggregate for 1 hr. Anti-CD18 blocking antibody was also added to
demonstrate that the observed aggregation was dependent on hCD18. LV:Chim.hCD18 was used at two different MOIs: lowMOI (LM 10 i.u./cell) and high MOI (100 i.u./
cell). (B) Soluble ICAM-1 binding assay. LFA-1 integrins were activated and thus cells were let to bind to sICAM-1 in the presence or absence ofMg2+ and EGTA for Ca2+
chelation. Chim LVwas used at two different MOIs: lowMOI (LM10 i.u./cell) and highMOI (100 i.u./cell). The significance of differences between groups is expressed as
*p< 0.05 and **p< 0.01. PBS, phosphate buffered saline; PMA, 4 beta-phorbol-12-myristate-13-acetate. See Supplementary Table S1 for list of antibodies used.
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confirming that the observed aggregation was de-
pendent on hCD18 expression (Fig. 2A).
In a second functional assay we measured the
ability of corrected LCs to bind to a soluble form of
the b2-integrin ligand ICAM-1 (sICAM-1) after a
proper stimulus. Nonactivated HD LCs showed a
low basal sICAM-1 binding capacity that markedly
increased after activation (Fig. 2B and Supple-
mentary Methods). LAD-I cells did not show any
sICAM-1 binding ability, either in the absence or in
the presence of activating agents. However, when
LAD-I cells were transducedwith any of the hCD18
LVs, these cells became able to bind to sICAM-1 at
levels comparable to those observed in HD cells
(Fig. 2B). Similar outcomes in the PMA-induced
aggregation and in the sICAM-1 binding assay were
observed in LAD-I LCs transduced with Chim
.hCD18 vector at 10 and 100 i.u./cell (Fig. 2A, B).
In vitro and in vivo lentiviral-mediated
phenotypic correction of CD18HYP mice
To test the efficacy of our LVs in an in vivomodel
we used CD18HYP mice, characterized by reduced
levels of mCD18 expression, high numbers of white
blood cells (WBCs), and reduced neutrophil emigra-
tion capacity upon an inflammation stimulus.28,29
Lin-BMcells fromCD18HYPmicewere transduced
with the hCD18-LVs and differentiated toward the
myeloid lineage in vitro. After differentiation 30–
40%hCD18+ cellswere detected,withno significant
differences among the different hCD18-LVs (Sup-
plementary Fig. S1A and SupplementaryMethods).
Similar levels ofmembranehCD18expressionwere
noted in these cells (Supplementary Fig. S1B), and
in all instances PMA stimulation increased the ex-
pression level of hCD18 (Fig. 3A), mimicking the
physiological response of endogenous CD18 to stim-
ulation.10 When the expression of the endogenous
CD11a was investigated, we observed that either
untransduced or eGFP-transduced CD18HYP cells
expressed about 50% of the levels corresponding
toWT cells. These levels increased to about 70–80%
of WT levels after transduction with any of the
hCD18-LVs (Fig. 3B), showing that exogenous
hCD18 is able to bind to the endogenous mCD11a
subunit, forming a b2 chimeric integrin.
To investigate the membrane expression levels
conferred by the different hCD18 LV in hemato-
poietic stem and progenitor cells (HSPCs), hCD18
MFI values were determined in undifferentiated
and myeloid differentiated CD18HYP Lin-Sca1+
cKit+ (LSK) BM cells previously transduced with
the different hCD18-LVs. As expected, when these
cells were transduced with an eGFP-LV, no differ-
ences in eGFP expression were observed between
the different populations (Fig. 3C and Supple-
mentary Table S1 for list of antibodies used).
Transduction with hCD18-LVs conferred hCD18
expression levels that were much lower, although
detectable, in LSK cells compared with levels de-
termined in the more differentiated cells (Fig. 3C),
indicating that all LVs mimicked the physiological
expression of CD18 in the different hematopoietic
compartments.30
When clonogenic assays with transduced sam-
ples were performed, similar numbers of colonies
were generated either in untransduced samples,
or in eGFP-transduced and hCD18-transduced
CD18HYP Lin-BM cells, indicating that neither the
lentiviral transduction nor the hCD18 expression
affected the clonogenic capacity of CD18HYP he-
matopoietic progenitors (Supplementary Fig. S1C).
In subsequent experiments, Lin- BM cells from
CD18HYP mice were transduced with hCD18-LVs
Figure 3. In vitro transduction of mouse hematopoietic progenitors. BM lin-
cells from CD18HYP mice were transduced for in vitro analyses at an MOI of 20
i.u./cell. (A) Surface expression of mCD11a in transduced and untransduced
myeloid-differentiated CD18HYPand CD18WT lin- cells. mCD11a surface ex-
pression levels were determined by flow cytometry and then normalized to
those found in untransduced CD18WT cells. (B) hCD18 regulation in response to
PMA in neutrophils generated in vitro from transduced CD18HYP lin- cells.
hCD18+ cells were determined by flow cytometry before and after PMA
stimulation. (C) hCD18 expression in LSK cells and Lin+ BMCs in vitro. See
Supplementary Table S1 for list of antibodies used.
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and then transplanted into lethally irradiated
CD18HYP recipients. As control groups, CD18HYP
mice were transplanted with either CD18WT or
CD18HYP Lin- BM cells transduced with an eGFP-
LV. In all instances, CD18HYP mice transplanted
with corrected CD18HYP BM cells showed the pres-
ence of hCD18+ leukocytes in PB (Fig. 4A). As ex-
pected, hCD18 was co-expressed with any of the
three mCD11 subunits (Supplementary Fig. S2).
Moreover, the ectopic expression of hCD18 signifi-
cantly increased the surface expression of mCD11a,
which was modestly expressed in eGFP-transduced
CD18HYP cells (Fig. 4B).
As in PB cells from WT mice, the analysis of PB
cells from GT-treated CD18HYP mice at 3 months af-
ter transplantation showed higher membrane levels
of expression of hCD18 in myeloid cells as compared
withBorT lymphoid cells, regardless of the promoter
used. However, the ratio of hCD18 expression in
myeloid versus lymphoid cells was higher in the
Chim.hCD18group(3.2-fold) than intheothergroups
(1.67 and1.87), and closer to the ratio observed inWT
mice (4.61-fold) (Fig. 4C). In all instances, VCNs/cell
in the range of 0.4–0.9 were detected in peripheral
blood lymphocytes (PBLs) from transplanted recip-
ients, indicating that differences observed among
the different LVs were not associated to differences
in the numbers of integrated copies (Supplementary
Fig. S3A). Four months after transplantation, pri-
mary recipients were culled and BMCs were also
analyzed for hCD18 and mCD11a expression. Per-
centages of hCD18+ cells ranged from 11% to 35%,
Figure 4. b2 integrins’ expression in gene therapy (GT)-treated CD18
HYP mice. Lin- cells from CD18HYP mice were isolated and transduced with hCD18-LVs.
Transduced cells were transplanted into lethally irradiated CD18HYP mice. As control groups, CD18HYP mice were transplanted with LV:SFFV.eGFP-transduced
CD18HYP and CD18WT lin- cells. (A) Percentage of hCD18+/mCD11a+ peripheral blood lymphocytes (PBLs) at 1 and 3mpt in ex vivo primary and secondary
GT-treated CD18HYP mice. (B) Mean of mCD11a surface expression levels (mean fluorescence intensity, MFI) in PBLs at the different time points after
transplant of transduced cells in primary (black) and secondary (scratched black) CD18HYP recipient mice and eGFP control animals (dark and light gray).
Presented results correspond to six independent experiments. The significance of differences between groups is expressed as ****p < 0.0001 and is always
referred to the CD18HYP + LV:SFFV.eGFP group. (C) Left Y axis shows the percentage of neutrophils, B-cells, and T-cells expressing hCD18 in ex vivo GT-treated
primary recipients. Right Y axis shows physiological mCD18 expression pattern. The upper numbers show the ratio of myeloid and lymphoid CD18 expression.
(D) Percentage of hCD18+ cells in total BMC population of primary and secondary recipients at 4 and 9 months posttransplantation, respectively. (E) mCD11a
surface expression levels observed in the BM of transplanted mice. The total number of transplanted animals on each transduction group for any of the hCD18
therapeutic vectors was as follows: in primary transplants, 34 Chim, 17 UCOE, and 27 PGK; in secondary transplants, 7 Chim, 5 UCOE, and 3 PGK. In the case of
control animals, 24 were transplanted with CD18HYP-GFP-transduced cells and 22 with CD18WT-GFP-transduced cells. The significance of differences between
groups is expressed as *p< 0.05 and **p< 0.01. See Supplementary Table S1 for list of antibodies used.
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similarly to data obtained in PB (Fig. 4D). Further-
more, also a similar mCD11a upregulation was ob-
served in total BMCs fromGT-treatedmice (Fig. 4E).
To evaluate if hCD18-LVs were able to trans-
duce true LT-HSCs, total BMCs from primary
recipients were re-transplanted into lethally irra-
diated CD18HYP secondary recipients. As in pri-
mary recipients, a significant number of PB and
BMCs from secondary recipients became hCD18+
(Fig. 4A) and upregulated mCD11a (Fig. 4B–E).
Because CD18 deficiency leads to defects in neu-
trophil extravasation from PB to inflamed tissues,
we investigated whether TNF-a-mediated neutro-
phil migration to a subcutaneous AP was restored
in GT-treated CD18HYP mice. A significant incre-
ment in the emigration ratio of neutrophils was
observed in WT mice treated with TNFa, whereas
no differences in this emigration ratio were ob-
served in CD18HYP mice (Fig. 5A). Significantly,
when the same study was performed with GT-
treated CD18HYP mice, a significant increase in the
TNF-a-induced emigration ratio was observed in
all groups of GT-treatedmice as compared with the
eGFP-LV group (Fig. 5A). This indicates that ec-
topic expression of hCD18 was able to restore
neutrophil migration of CD18HYP mice.
We also conducted a second functional assay
to evaluate whether the GT of CD18HYP mice im-
proved neutrophil migration ability based on an
LPS-induced asthma model. Mice were intrana-
sally treated with LPS, and a bronchoalveolar
lavage (BAL) was performed to collect alveolar
neutrophils that had migrated under the inflam-
matory stimulus. Whereas the donor migration
ratio of CD18HYP neutrophils was highly reduced
in comparison with CD18WT mice, a significant
increment in this neutrophil migration ratio was
observed in CD18HYP mice treated with Chim and
PGK hCD18-LVs (Fig. 5B).
In vitro functional correction of LAD-I-like
human CD34-derived granulocytes
We next investigated whether hCD18-LVs re-
stored the functional properties of LAD-like neu-
trophils.HDcord bloodCD34+ cellswere transduced
with an LV expressing an shRNA against the CD18
mRNA (LV:shCD18). As a control, an LV carrying
a scrambled shRNA (LV:shSCR) was also used.
The surface expression of hCD18 and hCD11a was
significantly reduced in LV:shCD18-transduced
cells in comparisonwithLV:shSCR-transduced cells
(Fig. 6A and Supplementary Methods). Moreover,
when the expression of these b2-integrin subunits
was analyzed by Q-PCR, a marked reduction in
hCD18 expression was observed, whereas CD11a ex-
pression levels remainedunchangedafterLV:shCD18
transduction (Fig. 6B), consistent with the speci-
ficity of the shRNA against hCD18 mRNA.
To generate CD18-deficient neutrophils in vitro,
CD34+ cells were cultured for 12 days in differen-
tiation media. An aliquot of LV:shCD18-transduced
cells was re-transduced with the therapeutic
Chim.hCD18-LV before differentiation. Whereas
the expression of hCD18, hCD11a, and hCD11b in
LV:shSCR-transduced cells was significantly re-
duced compared with their control group (Fig. 6C),
LAD-I-like cells transduced with the Chim.hCD18-
LV showed a 43% recovery of control hCD18 levels.
Similar increments in hCD11a and hCD11b ex-
pression were observed in corrected LAD-I-like
neutrophils (Fig. 6C).
Finally, two different functional assays were
carried out to evaluate if transduction of LAD-I-
like CD34+ cells with the Chim.hCD18-LV had an
impact on the functionality of in vitro differenti-
Figure 5. Correction of the LAD-I phenotype in ex vivo GT-treated CD18HYP
mice. (A) Air pouch-based inflammation model in ex vivo GT-treated pri-
mary CD18HYP recipients and control mice treated either with TNFa
(proinflammatory stimulus) or CMC (vehicle). Experiments were performed
4 months after transplantation. Neutrophil emigration ratio is calculated
from the total cell number found within the pouch and the percentage of
Gr1+ cells determined by flow cytometry. (B) Neutrophil migration to a
lung inflammation model based on LPS intranasal administration. The do-
nor neutrophil migration ratio is calculated from the percentage of Ly6G+
CD11c- donor neutrophils found in the bronchoalveolar lavage and in pe-
ripheral blood. The significance of differences between groups is ex-
pressed as *p < 0.05 and **p< 0.01.
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ated neutrophils. First, the adhesion capacity in a
dynamic setting was evaluated. In a flow chamber
assay, differentiated cells were allowed to attach to
fibrinogen under a fluid shear stress. LAD-I-like
neutrophils showed a decreased ability to resist
shear stress in comparison with control neutro-
phils (Fig. 6D). Such defects were significantly
corrected in Chim.hCD18-LV-transduced LAD-I-
like neutrophils, indicating that the ectopic ex-
pression of hCD18 restored, at least in part, the
adhesion properties of LAD-I-like human neutro-
phils (Fig. 6D). In a second functional assay we
evaluated the ability of in vitro differentiated
neutrophils to undergo a respiratory burst. While
control neutrophils were able to mount a rapid re-
spiratory burst in response to opsonized zymosan,
the respiratory burst of LAD-I-like neutrophils was
clearly diminished. Interestingly, gene-corrected
LAD-I-like neutrophils developed a respiratory
burst that was similar to that observed in control
cells (Fig. 6E).
DISCUSSION
LAD-I is a primary immunodeficiency leading to
the death of most severely affected patients within
the first two years of life. Despite the fact that allo-
geneicHSCT fromHLA-identical related donorshas
resulted in survival rates from 71% to 91% in LAD-I
patients,31–34 the access to these donors, together
with complications associated to the procedure,
constitutes the major limitation for this therapy.
HematopoieticGTwith improvedvectorshasproved
to be a promising approach for several monogenic
disorders and a powerful alternative to allogeneic
HSCT. Patients from different diseases, such as
Figure 6. Generation of LAD-I-like hematopoietic cells. Expression of b2-integrin subunits in LV:shSCR and LV:shCD18-transduced healthy cord blood CD34
+ after
6 days of culture. All transductions were performed at an MOI of 100 i.u./cell. (A) hCD18 and hCD11a surface expression levels. MFI values were normalized to MFI
values of untransduced cells. (B) hCD18 and hCD11a relative gene expression assessed by Q-PCR data using a DDCt method with GAPDH as an endogenous
reference gene and normalized to untransduced cells. (C) b2-integrins expression in LV:shSCR control, LAD-I-like, and LV:Chim.hCD18-corrected neutrophils obtained
by in vitro differentiation of cord blood CD34+ cells. Differentiation was carried out in the presence of SCF, IL3, and GCSF for up to 12 days. Expression levels were
determined by flow cytometry as MFI and then normalized to the MFI of untransduced cells. (D) Flow chamber experiments with LV:shSCR control, LAD-I like, and
LV:Chim.hCD18-corrected LAD-I-like neutrophils. Cells were allowed to attach to fibrinogen (ligand for CD11b:CD18 b2 integrins) and then nonadherent cells were
removed at low flow. Subsequently, flow rates were increased in 10–20 dyn/cm2 increments in 1min intervals to a maximum sheer stress of 80 dyn/cm2. The numbers
of attached cells after each increment of shear stress were calculated as the percentage of total number of adherent cells in the same field after a low flow wash.
(E) Respiratory burst on in vitro CD34+ cell-derived neutrophils. Respiratory burst response was induced by C3bi-opsonized zymosan (specifically recognized in a
CD11/CD18-dependent manner) and detected by luminol-enhanced chemoluminescence. Luminescence detected for each sample was extrapolated for 106 cells. The
significance of differences between groups is expressed as *p< 0.05, **p< 0.01, and ***p< 0.001. See Supplementary Table S1 for list of antibodies used.
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SCID-X1, ADA-SCID, WAS, B-Thal, ALD, or MLD,
have gained significant clinical benefits from this
new approach,35–37 without any evidence of inser-
tional oncogenesis using later-generation vectors.38
Although CD18 is expressed in all leucocytes and
also in HSPCs, levels of expression are particularly
high in differentiated myeloid cells. Therefore, we
aimed to investigate the therapeutic efficacy of dif-
ferent hCD18-LVswith either ubiquitous ormyeloid-
specific promoters. All previous reported data related
to the PGK promoter19–21,39 and the A2UCOE pro-
moter26,22,23 demonstrate their attractive safety pro-
file. To mimic the physiological expression of CD18,
we have also used a chimeric promoter with a pref-
erential expression in myeloid cells.27
When our hCD18-LVs were tested in vitro in a
human LAD-I cell line,9 full recovery, not only of
hCD18 but also of hCD11a subunit expression,
was obtained. The expression levels achieved were
similar to those found in HD cells and led to com-
plete phenotypic correction, as seen by the resto-
ration of the aggregation capacity and the ability to
bind to sICAM-1. These results indicated that all
tested hCD18-LVs were able to restore b2 integrin
expression and to correct the characteristic phe-
notype in LCs derived from a LAD-I patient.
Interestingly, when increasing doses of LV were
used for transduction, surface expression levels of
both subunits were rapidly saturated from anMOI
of 10 i.u./cell onward. This indicates that the en-
dogenous expression of hCD11 will limit the max-
imum amount of hCD18 ectopically expressed in
the membrane, which implies a relevant safety is-
sue favoring the GT of LAD-I patients
Our data in the CD18HYP mouse model are con-
sistent with previous studies showing that hCD18
can be expressed in the membrane of murine cells
coupled to its mCD11 counterpart, indicating that
both human and murine CD18 subunits might
function similarly in a mouse environment.8,10,40
Our data additionally show that neutrophils de-
rived from transduced CD18HYP lin- cells are able
to upregulate hCD18 expression upon PMA stim-
ulation. Moreover, when methylcellulose-based
colony-forming cell assays were performed, no dif-
ferences in the number of CFUs were observed
among untransduced, GFP-transduced, or hCD18-
transduced cells, indicating that neither the LV
transduction nor the ectopic expression of hCD18
mediates significant hematopoietic toxicity.
When BM-purified LSK cells were transduced
in vitro with any of the hCD18-LVs, the level of
hCD18 transgene expression obtained in all cases
was low, though significant in LSK progenitor cells,
while much higher in myeloid differentiated cells
(Fig. 3D), thus mimicking the physiological expres-
sion of mouse and human CD18. After transplan-
tation of hCD18-transduced CD18HYP BM cells into
CD18HYP mice, hCD18+ cells could be detected in
the PB of all GT-treated animals at a similar pro-
portion, in both primary and secondary recipients.
Moreover, these mice showed an upregulation in
mCD11a expression in comparison with mice
transplanted with eGFP-LV-transduced CD18HYP
cells, leading to the recovery of 50% of the levels
found in control mice transplanted with CD18WT
cells. This upregulation was maintained long-term
after transplantation as it was also observed in sec-
ondary recipients. hCD18 was expressed in T-cells,
B-cells, and neutrophils, irrespective of the pro-
moter used. However, neutrophils always showed
higher hCD18 levels than B- and T-cells, as hap-
pens with the physiological mCD18 expression in
these cells. This was observed in all GT-treated
mice, no matter the nature of the promoter used.
However, the ratio between the myeloid and lym-
phoid hCD18 expression was higher and closer to
the physiological ratio in the group corresponding
to the LV:Chim.hCD18.
Toevaluate theefficacyof thehCD18-LV-mediated
GT in the correction of the LAD-I phenotype in
CD18HYP mice, we analyzed neutrophil migration
capacity in two inflammatory settings: the TNFa-
inducedAPinflammationmodelandtheLPS-induced
pulmonary inflammation model. In both of them, ex
vivo GT-treated animals showed similar neutrophil
migration to WT controls, indicating the recovery of
the migration capacity of the donor neutrophils. It is
important tohighlight that ourdatashow, for thefirst
time in a mouse model, that GT restores in vivo
functional defects associated to CD18 deficiency.
To confirm the efficacy of the hCD18-LVs in pri-
mary human hematopoietic cells,CD18-knockdown
CD34+ cells were generated as target cells. This
strategy has been previously used to generate hu-
man models to study the efficacy of GT for other
diseases.41,42 Transduction of HD cord blood human
CD34+ cells with an LV construct expressing an
shRNA against hCD18 resulted in a 90% reduction
of hCD18 expression levels determined by Q-PCR
and by FACS, with a concomitant reduction in the
hCD11a surface expression levels. LAD-I-like neu-
trophils were generated in vitro showing surface
expression levels of hCD18, hCD11a, and hCD11b
drastically reduced in comparison with control
neutrophils.Moreover, LAD-I-like neutrophils were
unable to properly bind and they could not mount a
proper respiratory burst upon opsonized zymosan
activation. Interestingly, when LAD-I-like CD34+
cells were transduced with the chim.hCD18-LV and
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differentiated in vitro, a significant re-expression of
hCD18, hCD11a, and hCD11b was noted in the cell
membrane of differentiated neutrophils. Moreover,
an improved capacity tobind tofibrinogen, aswell as
a full restoration of theability tomounta respiratory
burst in response to opsonized zymosan, was noted
in these samples.
The preclinical results obtained in this study
suggest that any of the LVs generated in this study
may constitute good candidates for the ex vivo he-
matopoietic GT of LAD-I. While the PGK-LVs have
already demonstrated their efficacy and safety in
different clinical trials, the Chim.hCD18-LV con-
ferred CD18 expression levels slightly closer to
the physiological ones. Taken together, although
HSCT is nowadays the only curative therapy for
LAD-I, data presented in this study allow us to
strongly propose that GT with LVs expressing
hCD18 would constitute an attractive approach for
LAD-I patients lacking a related HLA-identical
donor.
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